Soma is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.

Medicinal name:
  • Carisoprodol 250 MG Oral Tablet [Soma]
  • Carisoprodol 350 MG Oral Tablet [Soma]
  • Aspirin 325 MG / Carisoprodol 200 MG / Codeine Phosphate 16 MG Oral Tablet [Soma Compound with Codeine]

Soma - Pharmacology:

Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.

Soma mini report

Soma NDA
NDA - A product marketed under an approved New Drug Application
Start - Stop data
Start - Stop data
not occurred

Soma for patients

Acromegaly is a rare and debilitating disease resulting from the overproduction of growth hormone (GH), most often due to a pituitary tumor. Overproduction of GH results in persistent elevation in levels of insulin-like growth factor I (IGF-I).

SOMAVERT is the first and only growth hormone receptor antagonist indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.

SOMAVERT selectively binds to GH receptors on all cell surfaces, where it blocks the binding of the bodys own GH. Reducing the amount of binding of the bodys GH results in decreased serum IGF-I levels.

SOMAVERT can be ordered by your physician through the Bridge ProgramTM, a specialty pharmacy and reimbursement assistance program that serves patients who are prescribed SOMAVERT.

If you have been diagnosed with acromegaly or suspect that you may have acromegaly, talk to your physician and ask if SOMAVERT is right for you.

Patients and any other persons who may administer SOMAVERT should be carefully instructed by a health care professional on how to properly reconstitute and inject the product.

Patients should be informed about the need for serial monitoring of LTs, and told to immediately discontinue therapy and contact their physician if they become jaundiced. In addition, patients should be made aware that serial IGF-I levels will need to be obtained to allow their physician to properly adjust the dose of SOMAVERT.

Soma Interactions

Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.

In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. The mechanism of this interaction is not known.

Soma Contraindications

SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components. The stopper on the vial of SOMAVERT contains latex.

Manufacturers name:

  • Meda Pharmaceuticals Inc
  • Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC
  • Rebel Distributors Corp
  • MedPointe Pharmaceuticals

Generic name, Overdose, Half Life Soma, Food Interactions, Chemical, etc..

Soma see also FDA report

Brand Names containing Pegvisomant